BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp

Reuters

2025/05/30

<a href="https://laohu8.com/S/BVAXF">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href="https://laohu8.com/S/HTFB">Horizon Technology Finance Corp</a>

BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement $(APA)$ with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539297433"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539297433\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539297433?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539297433","market":"us","top_or_hot":-1,"title":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVAXF\">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href=\"https://laohu8.com/S/HTFB\">Horizon Technology Finance Corp</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement <a href=\"https://laohu8.com/S/APA\">$(APA)$</a> with <a href=\"https://laohu8.com/S/HTFA\">Horizon Technology Finance Corporation</a> concerning the acquisition of former <a href=\"https://laohu8.com/S/IMVIF\">IMV Inc.</a> assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-30 08:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BVAXF\">BioVaxys Technology Corp.</a> Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with <a href=\"https://laohu8.com/S/HTFB\">Horizon Technology Finance Corp</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement <a href=\"https://laohu8.com/S/APA\">$(APA)$</a> with <a href=\"https://laohu8.com/S/HTFA\">Horizon Technology Finance Corporation</a> concerning the acquisition of former <a href=\"https://laohu8.com/S/IMVIF\">IMV Inc.</a> assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVIF","symbol_name":"IMV Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL4XYwbw:1","article_id":"2539297433","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539297433","pubTimestamp":1748565645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp. BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement  with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVIF":"IMV Inc.","BK4135":"资产管理与托管银行","BK4139":"生物科技","HRZN":"Horizon Technology Finance Corpo"},"translate_title":"BioVaxys Technology Corp.降低了与Horizon Technology Finance Corp修订后的资产购买协议中的融资里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVIF":0.9,"HRZN":0.9},"content_text":"BioVaxys Technology Corp. Lowers Capital Raise Milestone in Amended Asset Purchase Agreement with Horizon Technology Finance Corp\n\n\n        BioVaxys Technology Corp. has announced an update to its Asset Purchase Agreement $(APA)$ with Horizon Technology Finance Corporation concerning the acquisition of former IMV Inc. assets. The amended agreement, dated May 29, 2025, reduces the capital raise milestone required from USD $10 million to USD $2,028,636, which must be met by September 30, 2025. Additionally, BioVaxys will issue share purchase warrants to Horizon and Powerscourt Investments XXV LP as part of the consideration. The Licensing Earn-Out Payments Term has also been extended to August 11, 2033. All other terms of the APA remain unchanged. This announcement reflects BioVaxys's ongoing efforts to finalize the acquisition formalized in February 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovaxys Technology Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN99481) on May 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}